• Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
  • The company has also announced a new chronic kidney disease research program
  • CEO Chris Moreau sat down with Shoran Devi to discuss the news
  • Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
  • Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.

Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.

The company has also announced a new chronic kidney disease research program.

CEO Chris Moreau sat down with Shoran Devi to discuss the news.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.

More From The Market Online

@ the Bell: Tech drop takes a bite out of the TSX

Technology shares led the decliners as the sector endured its worst day in more than a month on the TSX, dragged down by crypto…

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

This company starts production at what could be Canada’s next great gold mine 

IAMGOLD (TSX:IMG) is a Canadian-based intermediate gold producer and developer focused on mining properties in North America and West Africa.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.